- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Acoramidis Significantly Reduces Mortality Risk in ATTR-CM Patients
Long-term data shows sustained benefits of early, continuous treatment with acoramidis
Mar. 31, 2026 at 3:24am
Got story updates? Submit your updates here. ›
BridgeBio Pharma presented long-term data from the ATTRibute-CM open-label extension trial, demonstrating that continuous treatment with acoramidis led to statistically significant reductions in all-cause mortality (44.7%) and cardiovascular mortality (49.3%) in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) through Month 54. The data also showed acoramidis mitigated the rise in NT-proBNP and stabilized heart failure-related quality of life scores.
Why it matters
Despite recent advancements, many ATTR-CM patients still face high mortality risk and limited long-term treatment options. These findings reinforce the importance of early diagnosis and prompt, durable treatment to deliver sustained clinical benefits for this patient population.
The details
The ATTRibute-CM open-label extension trial data showed that continuous acoramidis treatment led to the earliest timepoint in an open-label extension with this magnitude of risk reduction in all-cause and cardiovascular mortality events. Acoramidis also mitigated the rise in NT-proBNP, a marker of heart failure, to an extent not seen with other disease-modifying treatments. Additionally, early and continuous acoramidis stabilized and maintained heart failure-related quality of life scores.
- At Month 54, the trial data was presented.
- Acoramidis is approved by regulatory agencies including the U.S. FDA, European Medicines Agency, and others.
The players
Prem Soman, M.D., Ph.D.
Researcher from the University of Pittsburgh School of Medicine who presented the ATTRibute-CM data at the American College of Cardiology Annual Scientific Sessions & Expo.
BridgeBio Pharma, Inc.
The biopharmaceutical company that developed acoramidis and sponsored the ATTRibute-CM trial.
What they’re saying
“Despite dramatic therapeutic advances in the field, many patients with ATTR-CM still continue to suffer progressive heart failure, high mortality risk, and many have limited long-term treatment options.”
— Prem Soman, M.D., Ph.D., Researcher, University of Pittsburgh School of Medicine
“The ATTRibute-CM long-term data show that early and continuous treatment with acoramidis can meaningfully change the trajectory of this disease, with sustained reductions in all-cause and cardiovascular mortality, cardiovascular hospitalization, continued mitigation of NT-proBNP progression, and a favorable long-term safety profile.”
— Prem Soman, M.D., Ph.D., Researcher, University of Pittsburgh School of Medicine
What’s next
More data on the benefits of acoramidis for ATTR-CM patients is planned for future medical meetings.
The takeaway
These long-term results demonstrate that early and continuous treatment with acoramidis can significantly improve outcomes for ATTR-CM patients, highlighting the importance of prompt diagnosis and durable therapy to address this debilitating and often fatal condition.
